Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-05-04 16:27:24 ET · period of report 2026-05-01 · accession 0001680739-26-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-05-04 16:27 | 2026-05-01 | TVTX | Baynes Roy D. | Dir | M - OptEx | $6.82 | +9,750 | 47.2K | +26% | +$66.5K |
| DT | 2026-05-04 16:27 | 2026-05-01 | TVTX | Baynes Roy D. | Dir | S - Sale+OE | $44.22 | -9,750 | 37.5K | -21% | -$431.1K |
| DT | 2026-05-04 16:27 | 2026-05-01 | TVTX | Baynes Roy D. | Dir | M - OptEx | $0.00 | -9,750 | 9,750 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-01 | M | A | 9,750 | $6.82 | 47,250 | D | — | — | |
| 2 | Common | Common Stock | 2026-05-01 | S | D | 9,750 | $44.22 | 37,500 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. |
| 3 | Derivative | Stock option (right to buy) | 2026-05-01 | M | D | 9,750 | $0.00 | 9,750 | D | $6.82 · — to 2034-05-08 | 9,750 Common Stock | (F2) The stock option is fully vested and exercisable. |